|Bid||393.56 x 800|
|Ask||393.25 x 1100|
|Day's range||390.90 - 401.29|
|52-week range||230.93 - 444.65|
|Beta (3Y monthly)||0.73|
|PE ratio (TTM)||41.61|
|Earnings date||29 Oct 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||393.85|
Investing.com – Boston Beer (NYSE:SAM) surged on Thursday after Cowen upgraded its outlook on the beverage company, citing the explosive growth of its seltzer brand.
Molson Coors (TAP) gains from the solid brand portfolio and premiumization efforts as well as cost-saving initiatives and innovations. But soft beer demand and higher input costs remain deterrents.
Boston Beer (SAM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AB InBev (BUD) gains from the solid brand portfolio and geographic reach, with strength in global brands that are aiding the top line. But currency headwinds and commodity cost inflation are deterrents.
Momentum in the beer business positions Constellation Brands (STZ) for solid top and bottom-line growth in second-quarter fiscal 2020.
Should investors consider buying shares of Constellation Brands (STZ) as we head into the release of its second quarter fiscal 2020 earnings results, due out on Thursday, October 3?
Boston Beer (SAM) declares a new multiyear partnership with the National Hockey League (NHL) to promote its Truly Hard Seltzer brand. This will help it to offset softness in Samuel Adams brand.
The Zacks Analyst Blog Highlights: Anheuser-Busch, Tilray, Boston Beer, Constellation Brands and Aphria
Constellation Brands (STZ) witnesses strength in the beer business on strong shipment volume and depletions. But softness in the Wine & Spirits unit and Canopy Growth-related costs are headwinds.
On a day when trade worries and weak economic data hurt stocks, Medicines Company rose on a successful drug trial and Boston Beer fell following a downgrade.
Investing.com - Brewer Boston Beer (NYSE:SAM) slid in midday trading Tuesday following a downgrade, but it wasn’t on worries about beer consumption.
Monster Beverage (MNST) witnesses momentum in its energy drinks category driven by the Monster Energy brand. However, higher input and operating costs hurt margins.
September is usually a rocky month for stocks and is even gloomier after a downbeat August. With escalating trade tensions and an inverted yield curve, choppy trading sessions are expected to persist this month.
Diageo (DEO) displays solid momentum on strong fundamentals as well as innovation and expansion initiatives. This bolsters the company's performance over the years.
Keurig Dr Pepper (KDP) gains from strong in-market performance across most of its businesses and robust market share growth. Its acquisition and partnership strategy is also contributing to growth.
Brown-Forman's (BF.B) first-quarter fiscal 2020 results reflect impacts of tariffs and timing of customer orders despite strength in the United States.
AB InBev's (BUD) premiumization efforts as well as ongoing revenue management initiatives and strength in global brands position it for robust sales growth in the quarters ahead.
Boston Beer (SAM) remains committed to the three-point growth plan. Also, the company's focus on cost savings, long-term innovation, and the revival of Samuel Adams and Angry Orchard brands bode well.